{"id":"NCT02186873","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of Golimumab in Participants With Active Ankylosing Spondylitis","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFÎ± Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-03","primaryCompletion":"2015-12-15","completion":"2016-10-11","firstPosted":"2014-07-10","resultsPosted":"2017-11-13","lastUpdate":"2017-12-22"},"enrollment":208,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Golimumab","otherNames":[]}],"arms":[{"label":"Treatment Group 1: Placebo then Golimumab","type":"EXPERIMENTAL"},{"label":"Treatment Group 2: Golimumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic inflammatory disease of unknown etiology that involves the sacroiliac joints, and often the axial skeleton, entheses, and peripheral joints).","primaryOutcome":{"measure":"Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Group 1: Placebo Then Golimumab","deltaMin":26.2,"sd":null},{"arm":"Group 2: Golimumab","deltaMin":73.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":45,"countries":["United States","Australia","Canada","Germany","Mexico","Poland","Russia","South Korea","Ukraine"]},"refs":{"pmids":["37322274","35653615","35313978","32926247","29247154"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":103},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Alanine aminotransferase increased","Headache"]}}